Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2025-09-16 00:00:00 ET · period of report 2025-09-12 · accession 0001995218-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-16 | 2025-09-12 | LXEO | Townsend Richard Nolan | CEO, Dir | A - Grant | $2.64 | +2,193 | 222.3K | +1.0% | +$5,790 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-12 | A | A | 2,193 | $2.64 | 222,251 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). (F2) Includes 131,092 Restricted Stock Units. |